Products for Research Use Only
RegisterLogin

CDD-2789

CAT: 0804-HY-173149Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-173149Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
CDD-2789 is a highly selective small-molecule inhibitor targeting Activin receptor type 1 (ALK2, also known as ACVR1) . It blocks the SMAD1/5 signaling pathway mediated by ALK2/ALK1, thereby effectively suppressing downstream phosphorylation events induced by BMP and activin A. In the NanoBRET cellular model, CDD-2789 exhibits an inhibitory IC50 of 0.54 µM against ALK2. CDD-2789 holds promise for research on ALK2-related diseases, including diffuse intrinsic pontine glioma (DIPG), ependymoma, endometrial cancer, melanoma, non–small cell lung cancer, colorectal cancer, and pancreatic cancer[1].
CAS Number
3052084-77-9
UNSPSC
12352005
Target
Anaplastic lymphoma kinase (ALK) ; TGF-beta/Smad; TGF-β Receptor
Related Pathways
Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; TGF-beta/Smad
Field of Research
Cancer
Smiles
COC1=C(OC)C=C(C2=NC(C=CC(C(NCCCN(C)C)=O)=C3)=C3N2C4CCC4)C=C1OC
Molecular Formula
C26H34N4O4
Molecular Weight
466.57
References & Citations
[1]Jimmidi R, et al. Discovery of highly potent and ALK2/ALK1 selective kinase inhibitors using DNA-encoded chemistry technology. Proc Natl Acad Sci U S A. 2024 Nov 19;121 (47) :e2413108121.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-162565-01CDD-2807
HY-177143CDD-1498
HY-171248CDD-1115
HY-171247CDD-1281
HY-155143CDD-1733
HY-164145-01CDD-1653
HY-177141CDD-1154
HY-177140CDD-1147
HY-176885CDD-2211
HY-176884CDD-2110

Alternative Products

CatalogName
GTR19258447-01CDD-2789
T210217-01CDD-2807
T89314-01CDD-3290
T88619-01CDD-1653
T79346-01CDD-1845
T79345-01CDD-1733
GTR19250024-01CDD-1115
GTR19249583-01CDD-1431
GTR17975534Cdd Antibody
GTR19273455-01CDD-2110

Popular Products